Letter from TAG and other advocates expressing concerns about proposed Medicaid criteria that will limit access to sofosbuvir and other lifesaving hepatitis C medications.
Letter asking to speak to key staff at Novartis to discuss its support of the clinical research required to more fully understand the efficacy of Menveo in adolescents and adults living with HIV.
Follow-up to January 14, 2014 letter regarding the development of a plan to end AIDS in New York State.
February 13, 2014 TAG, CRAG, and the TB CAB sent an open letter to AstraZeneca urging their continued investment in tuberculosis research despite the cessation of AstraZeneca’s Neglected Tropical Diseases, Tuberculosis, and Malaria Program. Read/Download the TAG, CRAG, TB CAB…
This letter from CRAG (TB Community Research Advisors Group) and TAG was sent to Anne Whitaker, President, North America Pharmaceuticals of Sanofi US. It commends Sanofi for making this commitment to lower the price of rifapentine for Public Health Service…
TAG, CRAG, and the TB CAB issues urgent appeal for Otsuka to initiate its long overdue compassionate use program by the end of 2013.
167 Organizations and 513 Individuals Signed on to Letter to Secretary Sebelius on the Allowance of Co-pay Assistance in the ACA Health Plans
TAG and 134 other organizations sent this letter to underscore the need for a swift response from UNITAID to hepatitis C virus (HCV) coinfection; delays will cost lives and impede scale-up when more effective and tolerable therapies are available.
We are writing to express serious concern and dismay regarding the shutting down of the website for the Conference on Retroviruses and Opportunistic Infections (CROI).
A broad coalition of HIV/AIDS advocates and advocacy organizations urge patient groups to support the AllTrials Initiative.